5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close

The piece highlights the price-to-book (P/B) ratio as a valuation tool and presents a Zacks-screened list of five low P/B stocks with Buy indications: AES (Zacks Rank 2, Value Score A, 3–5yr EPS growth 11.2%), BorgWarner (BWA, Rank 2, Value Score A, 10.2%), EnerSys (ENS, Rank 1, Value Score B, 15.0%), PG&E (PCG, Rank 2, Value Score A, 15.9%) and Keros Therapeutics (KROS, Rank 1, Value Score A, 36.5%). The screening criteria include P/B and P/S below industry medians, PEG <1, minimum $5 price, 20-day volume ≥100k, Zacks Rank ≤2 and Value Score A/B — signaling a value-oriented, tradable shortlist for investors seeking undervalued names across utilities, energy, automotive/EV supply and biotech.

Analysis

Market structure: The P/B screen signals a rotation back into capital-intensive, tangible-asset names — utilities (PCG, AES) and industrial battery/supplier plays (ENS, BWA) — plus a high-volatility biotech (KROS). Winners: regulated cash-flow generators and battery/EV supply-chain vendors; losers: pure software/services and asset-light growth names as value reallocation and higher-rate scrutiny favor balance-sheet-rich firms. Cross-asset: stronger utility bids can tighten credit spreads (improve IG bonds) but elevate equity tail-risk pricing (higher put demand) where liability risk exists.

Competitive dynamics: EV adoption and replacement cycles favor ENS and BWA (battery and powertrain components) over legacy ICE suppliers; AES benefits from renewables scale but remains rate-sensitive. PCG retains local pricing power but is constrained by regulatory/legal overhangs that cap valuation until wildfire/settlement clarity is achieved. Low P/Bs often reflect accounting/pension/impairment risk rather than pure bargain — screening must adjust book value for intangibles and deferred liabilities.

Risk assessment: Tail risks — PCG: large wildfire or regulatory fine (>$5–10bn) within 12–24 months; KROS: binary trial failure within 6–18 months wiping >75% equity value; BWA: margin compression from commodity or warranty cost shocks within 3–9 months. Time horizons: immediate (days) react to earnings/clinical readouts; short-term (3–6 months) for re-rating on guidance; long-term (3–5 years) for structural growth (EPS CAGR 10–36% per Zacks).

Trade implications: Size positions small and hedge tails: prefer selective longs in ENS and AES (balance-sheet plus secular demand) and a tiny, options-based position in KROS for asymmetric upside. Use puts or CDS to cap downside on PCG given idiosyncratic liability risk. Consider pair trades that go long battery/supplier ENS and short broader auto supplier ETF if macro auto demand softens; enter now, scale up on any 15–25% pullback, take profits at +30–50% or upon realization of catalyst.

Key Decisions for Investors

• Establish a 2–3% long position in Enersys (ENS) over next 2 weeks: thesis = secular battery replacement and 15% mid-term EPS CAGR; use covered-call overlays to harvest yield if IV <25%, add an extra 1% on any >15% pullback.
• Build a 1.5–2% long position in AES (AES) as a renewables/utility value play, hold 6–18 months; hedge duration sensitivity by buying 2-3% notional of 2–3 year OTM interest-rate receiver protection or reduce position if 5y Treasury yield rises >75bp from current levels.
• Allocate 0.5–1% speculative allocation to Keros Therapeutics (KROS) via limited-risk options: buy Jan‑2027 LEAP calls or a 6–12 month call spread sized to cost ≤0.5% portfolio; target 30–50% upside exit or cut to zero on negative pivotal data within 12 months.
• Take a hedged PCG position: if buying PCG, size 1.5–2% long and simultaneously buy 18–24 month OTM puts (~10–15% OTM) or purchase CDS protection sized to limit loss to ~5% portfolio exposure; reduce or exit if regulatory settlement >$2bn or if stock rises >40% from today.
• Implement a pair trade: go long BorgWarner (BWA) 1–2% and short a broad auto-supplier ETF (10–15% notional of the long) to isolate EV-content share gains; add to the long on <15% drawdown, close the short if BWA outperforms by >25% relative in 6 months.